1. United Kingdom Stocks

  2. •

    Health services

  3. •

    Medical/Nursing services
Fusion Antibodies Plc

Fusion Antibodies Plc

LLSE:FAB
5.75
GBX
0.00
(0.00%)
1.56BMarket Cap
Dec 07Next Earn
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
0.04
0.07
0.09
0.17
0.1
0.18
0.16
0.18
0.11
0.02
0.02
0.02
- -
Basic EPS, GAAP
- -
0.05
0.01
-0.04
-0.06
-0.03
-0.11
-0.05
-0.1
-0.04
-0.02
-0.01
- -
Free Cash Flow per Basic Share
-0.01
0.01
-0.01
-0.02
-0.11
-0.01
-0.06
-0.02
-0.07
-0.03
-0.01
-0.01
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.01
0.07
0.08
0.3
0.24
0.22
0.19
0.14
0.04
0.02
0.01
0.01
0.01
Tangible Book Value per Share
0.01
0.07
0.08
0.3
0.24
0.22
0.19
0.14
0.04
0.02
0.01
0.01
0.01
Basic Weighted Avg Shares
22
22
22
16
22
22
25
26
26
56
96
115
115
Sales/Revenue/Turnover
1
1
2
3
2
4
4
5
3
1
2
2
- -
Operating Margin (%)
-10.86
1.87
6.61
-26.41
-69.11
-27.19
-29.99
-27.61
-98.52
-201.32
-86.11
-57.91
- -
Depreciation Expense
- -
- -
- -
- -
- -
1
1
1
- -
- -
- -
- -
- -
Net Income, GAAP
- -
1
- -
-1
-1
-1
-3
-1
-3
-2
-2
-1
- -
Effective Tax Rate (%)
- -
- -
4.73
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-9.36
77.91
6.27
-26.01
-57.93
-17.89
-69.6
-25.01
-89.49
-195.95
-82.75
-54.45
- -
Working Capital
- -
- -
- -
5
3
2
4
3
1
2
1
2
2
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
- -
1
2
7
5
5
5
4
1
2
1
2
2
Return on Invested Capital (%)
- -
- -
7.66
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
7.62
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
141.93
7.58
-16.9
-21.19
-13.71
-60.65
-28.47
-108.01
-152.67
-127.58
-96.64
- -

Capital Structure

GBP

•

in mil. unless spec.
Mar'25
Sep'26
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
105
114
125
Market Capitalization
6
20
16

Working Capital

GBP

•

in mil. unless spec.
Mar'25
Sep'26
Mar'26
Total Current Assets
1
1
2
Cash, Cash Equivalents & STI
- -
- -
1
Accounts Receivable, Net
- -
1
1
Inventories
- -
- -
- -
Total Current Liabilities
1
1
1
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

GBP

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
29.69%
4.89%
114.55%
Free Cash Flow
110.5%
22.92%
-14.63%
Net Income, GAAP
-43.43%
-2.56%
-29.34%
Sales/Revenue/Turnover
13.15%
-0.96%
7.38%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
1
2025
- -
- -
2
2026
- -
- -
2

Semi-annual Earnings Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.04
2025
- -
- -
-0.02
2026
- -
- -
-0.01

Semi-annual Dividends Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Adrian Robert Kinkaid
Full Time Employees
27
Sector
Health services
Industry
Medical/Nursing services
Address
Springbank Industrial Estate Dunmurry BF United Kingdom BT17 0QL
IPO Date
Dec 18, 2017
Website
fusionantibodies.com
Similar Companies
Hims & Hers Health, Inc. (NYSE:HIMS)
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)
Mobile-health Network Solutions (NASDAQ:MNDR)
Dr. Lal PathLabs Limited (NSE:LALPATHLAB)
Tenon Medical, Inc. (NASDAQ:TNON)
Teladoc Health, Inc. (NYSE:TDOC)
Business
Fusion Antibodies plc specializes in preclinical antibody discovery, engineering, and supply services for therapeutic drug and diagnostic applications, offering monoclonal antibody discovery and development; antibody sequencing, engineering, and humanization using its proprietary CDRx™ platform; rational affinity maturation; recombinant protein expression; and stable cell line development including cGMP scale-up. Established in 2001 as a spin-out from Queen’s University Belfast and headquartered in Belfast, the company serves a global client base including eight of the top ten global pharmaceutical companies. Recent strategic developments include an expanded collaboration agreement with the US National Cancer Institute to humanize camelid nanobodies for CAR-T therapy applications, and selection by a major European-based global pharmaceutical firm for a multi-target integrated therapeutic antibody services project covering humanization and supply, expected to generate significant revenue. Additionally, Fusion Antibodies secured up to £545,000 in Innovate UK funding to advance a DR5 antibody for treatment-resistant cancers and announced new R&D projects including a bispecific antigen toolkit. The company maintains ongoing revenue growth and broader platform development under CEO Adrian Kinkaid's leadership, aiming to reduce dependence on smaller clients by targeting major pharmaceutical collaborations and leveraging novel technologies in antibody engineering and development. Fusion Antibodies maintains operations primarily in the UK and collaborates internationally across the pharmaceutical and biotech sectors to accelerate drug discovery and therapeutic innovation.